33rd week of 2013 patent applcation highlights part 55 |
Patent application number | Title | Published |
20130210875 | Novel binding site of IKK-beta - Uses and applications derived from the discovery of a novel binding site of IKK-β, such as method of screening a therapeutic agent as drug candidate for treating cancer, inflammation, or other diseases/disorders, are provided. | 2013-08-15 |
20130210876 | ALPHA-2 ADRENERGIC AGONIST HAVING LONG DURATION OF INTRAOCULAR PRESSURE-LOWERING EFFECT - The present invention provides a method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole, or a salt thereof to the affected eye of a patient, as a single dose, wherein the affected eye maintains an intraocular pressure less than the baseline thereafter. | 2013-08-15 |
20130210877 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES - The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection. | 2013-08-15 |
20130210878 | BENDAMUSTINE COMPOSITIONS AND METHODS THEREFORE - Aqueous Bendamustine formulations with improved stability are disclosed. Especially preferred formulations are low-dose ready-to-use liquid formulations in which Bendamustine is in a non-aqueous vehicle in combination with an aqueous phase that contains significant quantities of chloride. | 2013-08-15 |
20130210879 | FORMULATIONS OF BENDAMUSTINE - Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid contains a mixture of PEG and PG; an organic or inorganic compound in an amount sufficient to obtain a pH of from about 6.0 to about 11 for the polyethylene glycol, as measured using USP monograph for polyethylene glycol; and optionally an antioxidant. The bendamustine-containing compositions have less than about 5% total esters, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C. | 2013-08-15 |
20130210880 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY - The present invention relates to isoindoline derivatives of the formula (I) | 2013-08-15 |
20130210881 | ANTIMICROBIAL COMPOSITION - The present disclosure relates to an antimicrobial composition comprising at least one polymer or oligomer, the polymer and oligomer being comprised of repeating units of hydrophilic heterocyclic amine monomers that are coupled by hydrophobic linkers selected to confer the antimicrobial activity to the composition, methods of producing the same and uses of the antimicrobial composition. | 2013-08-15 |
20130210882 | PLANT DISEASE CONTROL COMPOSITION AND ITS USE - A plant disease control composition comprising a carboxamide compound represented by following formula (I), wherein R | 2013-08-15 |
20130210883 | LIPASE INHIBITORS - The invention provides a compound of formula (I) as defined herein | 2013-08-15 |
20130210884 | Methods for Identifying Analgesic Agents - The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations. | 2013-08-15 |
20130210885 | CRYSTALLINE FORMS OF L-MALIC ACID SALT OF SUNITINIB - The present invention relates to crystalline forms of L-malic acid salt of sunitinib and its preparation. The crystalline forms of the present invention are designated as Form V and Form VI of L-malic acid salt of sunitinib. Formula (I). | 2013-08-15 |
20130210886 | Novel Derivatives Useful as Antiviral Agents - The invention relates to compounds of formula (I) for use in the prevention and/or treatment of viral infections: Wherein X, Y, Z, T, R | 2013-08-15 |
20130210887 | DENDRIMERS AS NON-VIRAL VEHICLES FOR GENE THERAPY - The present invention relates to novel compounds of general formula (I) and (II) for their use in gene therapy as non-viral vehicles and their use for the preparation of a medicament. It also discloses the process of synthesis of said compounds of general formula (I) and (II). | 2013-08-15 |
20130210888 | Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1 - LSD1, a homolog of nuclear amine oxidases, functions as a histone demethylase and transcriptional co-repressor. LSD1 specifically demethylates histone H3 lysine 4, which is linked to active transcription. Lysine demethylation occurs via an oxidation reaction that generates formaldehyde. Importantly, RNAi inhibition of LSD1 causes an increase in H3 lysine 4 methylation and concomitant de-repression of target genes, suggesting that LSD1 represses transcription via histone demethylation. The results thus identify a histone demethylase conserved from | 2013-08-15 |
20130210889 | COMPOSITION AND METHOD FOR INNER EAR SENSORY HAIR CELL REGENERATION AND REPLACEMENT - A composition and method for replacement and regeneration of hair cells of the inner ear is provided. The composition comprises an active agent in an amount effective to decrease Hes1 gene expression in a tissue of the inner ear. The active agent can be short interfering RNA (siRNA) molecules encapsulated in a biodegradable nanoparticle. The method involves administering a solution to the inner ear where the solution contains an active agent in an amount effective to decrease Hes1 gene expression. | 2013-08-15 |
20130210890 | CANCER THERAPY - The present invention provides agents useful in the treatment of cancer, as well as systems for identifying and/or characterizing such agents, and systems for identifying and/or characterizing patient populations responsive to particular agents. | 2013-08-15 |
20130210891 | PHARMACEUTICAL COMPOSITION FOR TRANSCOLONIC ABSORPTION - The present invention aims to provide a pharmaceutical composition for transcolonic absorption capable of delivering a physiologically active substance (in particular, a water-soluble physiologically active substance of high molecular weight) having an intracellular site of action into specific tissue cells with high specificity, noninvasively by a means of administration other than injection. The pharmaceutical composition for transcolonic absorption of the present invention is characterized by comprising at least the following (a) and (b); | 2013-08-15 |
20130210892 | Method of Treatment - A method of treating autoimmune and inflammatory diseases or conditions in a mammal, such as a human, which comprises the administration of a inhibitor of the bromodomain-containing protein: SP110 | 2013-08-15 |
20130210893 | TREATMENT OF INTERFERON-RELATED DEVELOPMENTAL REGULATOR 1 (IFRD1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IFRD1 - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Interferon-related developmental regulator 1 (IFRD1), in particular, by targeting natural antisense polynucleotides of Interferon-related developmental regulator 1 (IFRD1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IFRD1. | 2013-08-15 |
20130210894 | APPLICATION OF HIGHLY CONSERVED DOMAIN SEQUENCES FROM VIRAL GENOME AS TEMPLATE TO DESIGN THERAPEUTIC SLIRNAS - This invention relates to the application of the highly conserved sequences of viral genome, especially from a highly conserved domain of enteroviral genome as templates to design target small ligand RNAs (sliRNAs). The resulting sliRNAs are therapeutically active ingredients in the treatment of the related diseases caused by pathological angiogenesis. | 2013-08-15 |
20130210895 | rAAV-Guanylate Cyclase Compositions and Methods for Treating Lebers Congenital Amaurosis-1 (LCA1) - Disclosed are viral vector compositions comprising polynucleotide sequences that express one or more biologically-active mammalian guanylate cyclase proteins. Also disclosed are methods for their use in preventing, treating, and/or ameliorating at least one or more symptoms of a disease, disorder, abnormal condition, or dysfunction resulting at least in part from a guanylate cyclase deficiency in vivo. In particular embodiments, the use of recombinant adeno-associated viral (rAAV) vectors to treat or ameliorate symptoms of Leber's congenital amaurosis, as well as other conditions caused by an absence or reduction in the expression of a functional retinal-specific guanylate cyclase 1 (retGC1). | 2013-08-15 |
20130210896 | Immunotheraphy of Brain Tumors Using a Nanoparticle CpG Delivery System - One aspect of the invention relates to a nanoparticle conjugated CpG (NANO-CpG) composition and pharmaceutical composition thereof, and the preparation methods thereof. Another aspect of the invention relates to a method for using the NANO-CpG to improve CpG delivery into brain tumor associated inflammatory cells in a subject. Another aspect of the invention relates to a method for treating or preventing a method for treating and/or preventing a brain tumor in a subject comprising administering a therapeutically effective amount of the NANO-CpG or a pharmaceutical composition thereof to the subject. In one embodiment, a subject treated with the NANO-CpG composition disclosed herein or a pharmaceutical composition thereof developed immunity to brain tumor. | 2013-08-15 |
20130210897 | MINI-INTRONIC PLASMID VECTORS - Compositions and methods are provided for achieving persistent, high level expression of transgenes in vitro and in vivo. Aspects of the invention include vectors comprising an intronic cassette that comprises plasmid elements, and methods that rely on the use of vectors comprising an intronic cassette that comprises plasmid elements. These compositions and methods find use in many applications, including therapeutic applications such as in gene therapy; synthesis applications such as in the synthesis of peptides, proteins, and RNAs, e.g. for research or therapeutic purposes; and research applications, such as in the production of transgenic cells and animals. In addition, reagents, devices and kits thereof that find use in making the subject compositions and practicing the subject methods are provided. | 2013-08-15 |
20130210898 | RECOMBINANT VIRUSES AND THEIR USE FOR TREATMENT OF ATHEROSCLEROSIS AND OTHER FORMS OF CORONARY ARTERY DISEASE AND METHOD, REAGENT, AND KIT FOR EVALUATING SUSCEPTIBILITY TO SAME - Recombinant viruses comprising a heterologous. DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies. | 2013-08-15 |
20130210899 | Method and Therapeutic for the Treatment and Regulation of Memory Formation - A methodology and pharmaceutical and gene therapies for the treatment and regulation of memory function are provided. The invention identifies specific HDAC, and in particular, HDAC3 and HDAC4 as negative regulators of memory formation and specifically targets one or both HDAC3 and HDAC4 for down-regulation. By specifically targeting HDAC3 and HDAC4 with small molecule inhibitors and gene therapies it is possible to provide a powerful therapeutic approach to facilitate gene expression during memory formation that can lead to the regulation and treatment of memory disorders. | 2013-08-15 |
20130210900 | ARID1A and PPP2R1A Mutations in Cancer - Two genes, ARID1A (AT-rich interactive domain-containing protein 1A) and PPP2R1A (protein-phosphatase 2, regulatory subunit 1, alpha), can be used in methods which are useful for detecting cancer, diagnosing cancer, contributing to a diagnosis of cancer, confirming a diagnosis of cancer, identifying appropriate treatments for cancer, monitoring treatment of cancer, and evaluating treatment protocols for cancer, including ovarian clear cell carcinoma, breast cancer, colon cancer, gastric cancer, lung cancer, medulloblastoma, pancreatic cancer, and prostate cancer. | 2013-08-15 |
20130210901 | METHOD OF TREATING NEURODEGENERATIVE DISEASES - An agent which upregulates an amount or activity of a heterogeneous nuclear ribonucleoproteins A/B (hnRNP A/B) polypeptide is disclosed, for use in treating a neurodegenerative disease. Pharmaceutical compositions comprising same are also disclosed. | 2013-08-15 |
20130210902 | MODIFIED HUMAN U1SNRNA MOLECULE, A GENE ENCODING FOR THE MODIFIED HUMAN U1SNRNA MOLECULE, AN EXPRESSION VECTOR INCLUDING THE GENE, AND THE USE THEREOF IN GENE THERAPY - A modified human U1snRNA molecule is described, the target sequence of which is located in a region of the pre-mRNA of the target gene comprised between 2 and 50 base pairs downstream of an exon/intron junction site, which is capable of restoring the correct splicing of a target gene of therapeutic interest bearing a mutation which induces exon skipping and resulting in a genetic disease. Modified human U1snRNA molecules are described by way of example for the correction of diseases associated with exon skipping, such as spinal muscular atrophy, hemophilia B, and cystic fibrosis. | 2013-08-15 |
20130210903 | APTAMERS TO GLYCOPROTEIN VI - The present invention relates, in general, to glycoprotein VI (GPVI) and, in particular, to aptamers to GPVI and to compositions comprising same. The invention also relates to methods of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of GPVI. The invention further relates to antidotes to GPVI aptamers and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention also relates to aptamers that bind to and enhance the activity of GPVI. | 2013-08-15 |
20130210904 | SYNTHESIS OF BICYCLIC COMPOUNDS AND METHOD FOR THEIR USE AS THERAPEUTIC AGENTS - Disclosed embodiments concern the synthesis and use of therapeutic compounds that for treating emerging flu strains and minimizing resistance to such strains. Methods for making the disclosed compounds concern using a base-mediated addition/cyclization sequence followed by functional group manipulation to develop functionalized compounds that can target neuraminidase, which makes them ideal candidates for treating influenza. Pharmaceutical compositions comprising the therapeutic compounds and biologically-acceptable materials are also described. Methods of inhibiting neuraminidase in subjects that are suspected of containing neuraminidase are also described. The use of metabolites of the disclosed compounds can also be used in diagnostic assays for therapeutic dosing of the disclosed compounds. | 2013-08-15 |
20130210905 | Selective Ablation of Pain-Sensing Neurons by Administration of a Vanilloid Receptor Agonist - The present invention provides methods and kits for the selective ablation of pain-sensing neurons. The methods comprise administration of a vanilloid receptor agonist to a ganglion in an amount that causes death of vanilloid receptor-bearing neurons. Accordingly, the present invention provides methods of controlling pain and inflammatory disorders that involve activation of vanilloid receptor-bearing neurons. | 2013-08-15 |
20130210906 | COMPOUNDS, METHODS OF PREPARATION AND USE THEREOF FOR TREATING CANCER - The present invention provides two compounds, namely Compound A and B, as the potential anticancer drug, and a composition comprising said Compound A and/or B for treating cancer or tumor related diseases. The present invention also relates to methods of preparing the compounds from a natural source and a composition comprising the compounds, and using the same for treating cancer or tumor related diseases. | 2013-08-15 |
20130210907 | METHOD FOR PREVENTING OR TREATING ENTEROCHROMAFFIN CELL HYPERPLASIA-RELATED DISEASES BY QUERCETIN ADMINISTRATION - The present invention provides methods and compositions for preventing or treating enterochromatffin cell hyperplasia-related diseases. The compositions comprise a therapeutic effective amount of Quercetin, glycosylated Quercetin, or mixture thereof. The methods comprises administering said composition as well as preparing said composition as a pharmaceutical formulation, | 2013-08-15 |
20130210908 | STABILIZED ANTHOCYANIN COMPOSITIONS - The invention describes stabile anthocyanin compositions, methods to prepare such compositions and also methods of use of such compositions to treat various afflictions. The present invention describes unique compositions of an anthocyanin and a stabilizing compound such that the combination of the two components provides that the anthocyanin does not readily undergo degradation, such as oxidation, pH instability, etc. | 2013-08-15 |
20130210909 | COUMARIN-CHALCONES AS ANTICANCER AGENTS - The present invention relates to certain coumarin/chalcone compounds or a pharmaceutically acceptable salt thereof. The present invention particularly relates to the coumarin/chalcone compounds as anticancer agents useful for the treatment of cancer. The present invention also relates to the process of preparation of the said compounds. | 2013-08-15 |
20130210910 | COMPOSITIONS SUITABLE FOR THE TOPICAL TREATMENT OF FUNGAL INFECTIONS OF THE SKIN AND NAILS - The present invention relates to pharmaceutical compositions suitable for the topical treatment of fungal infections of the skin and nails, such as tinea pedia and tinea cruris, among others. The active ingredients of the present compositions are low molecular weight organic acids and their salts, many of which are previously known as antifungal agents to some degree but which, when used in combination, produce a synergistic enhancement in antifungal potency such that the combined effect is greater than that when used by the agents alone. The antifungal activity of the active ingredients is further enhanced through the use of non-volatile hygroscopic solvents rather than the aqueous or volatile organic solvents used in the art. | 2013-08-15 |
20130210911 | METHOD AND COMPOSITION FOR TREATING A DISEASE OR CONDITION RELATED TO OREXIN RECEPTOR 1, OREXIN RECEPTOR 2, SOMATOSTATIN RECEPTOR 2 OR DOPAMINE D2L RECEPTOR - Disclosed herein are methods and composition for treating a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine D | 2013-08-15 |
20130210912 | Ophthalmic Pharmaceutical Compositions and Methods of Making and Using Same - A stable ophthalmic pharmaceutical composition for relief, treatment, control, alleviation, or prevention of a pathological ocular condition of the eye comprises: (a) a first polymer, a viscosity of which changes with a change in a concentration of an electrolyte, such as a salt, when added to said first polymer; (b) a second polymer that is different from the first polymer and can modify the viscosity of the first polymer; and (c) an oil. In some embodiments, the composition further comprises a non-ionic surfactant. The composition can form a stable oil-in-water emulsion on storage, but separate into an oil phase and a water phase when applied in the eye. The emulsion can comprises an ophthalmic active pharmaceutical ingredient dissolved in the oil or water phase. The emulsion can provide enhanced stability to said active pharmaceutical ingredient. | 2013-08-15 |
20130210913 | ANTI-TUMOR AND ANTI-INFLAMMATORY DICINNAMOYL-GLYCEROL ESTERS AND THEIR ANALOGUES - Synthetic dicinnamate compounds and their analogues are disclosed that exhibit anti-tumor activity and/or an anti-inflammatory activity, and have beneficial activity principally in destroying cancer cells. Furthermore, methods for the extraction of the extracts are disclosed. | 2013-08-15 |
20130210914 | METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS - The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders. | 2013-08-15 |
20130210915 | ANTIVIRAL COMPOUNDS - The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections. | 2013-08-15 |
20130210916 | THERMALLY STABLE OIL-IN-WATER EMULSIONS CONTAINING AN OIL THAT CONTAINS POLYUNSATURATED FATTY ACIDS - The present invention relates to thermally, stable oil-in-water emulsions comprising an oil comprising a polyunsaturated fatty acid, water, an emulsifier, and a water-soluble stabilizer, and processes for preparing the thermally stable oil-in-water emulsions. The thermally stable oil-in-water emulsions remain flowable at a temperature of −40° C., and are free from a variation in particle size after 9 months in storage at a temperature of −40° C. to −15° C. | 2013-08-15 |
20130210917 | Nitrated Lipids and Methods of Making and Using Thereof - Described herein are nitrated lipids and methods of making and using the nitrated lipids. | 2013-08-15 |
20130210918 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS - The invention provides methods of treating Friedreich's ataxia using histone deacetylase inhibitors. | 2013-08-15 |
20130210919 | NOVEL CRYSTALLINE FORMS OF (1S,2R)-2-(AMINO METHYL)-N,N-DIETHYL-1-PHENYL CYCLOPROPANE CARBOXAMIDE - The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described. | 2013-08-15 |
20130210920 | DESENSITIZING DRUG PRODUCT - Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products. In one embodiment, the desensitizing drug products are male genital desensitizers that comprise one or anesthetic agents and one or more melting point depressing agents. | 2013-08-15 |
20130210921 | Method for Giving Warmth to Skin - A method for giving warmth to skin, wherein an external composition for skin is provided, which gives good warmth without inducing irritation or pain and whose sustainability of warmth is good. The external composition for skin contains (A) an agent for giving warmth and (B) at least one member selected from the group consisting of fatty acid esters of aliphatic polyhydric alcohols and aromatic carboxylic acid esters of lower alcohols or aliphatic polyhydric alcohols. | 2013-08-15 |
20130210922 | STABLE READY TO USE INJECTABLE PARACETAMOL FORMULATION - The invention concerns a stable aqueous paracetamol solution for use in IV infusion comprising at least one stabilizing-dissolving compound for paracetamol in solution selected from the group consisting of cyclodextrins, at least one stabilizing compound bearing at least one thiol functional group and at least one stabilizing compound selected from the group consisting of Thiamine salts. | 2013-08-15 |
20130210923 | Antimicrobial Hand Soap Composition - Topical aqueous liquid compositions for application to the epidermis which provide a germicidal benefit thereto comprising: 0.02-10% wt. of a germicidally effective amount of a quaternary ammonium surfactant compound, 0.1-25% wt. of at least one anionic surfactant constituent which excludes anionic surfactants of the sulfate and sulfonate types, 0.1-15% wt. of a cationic conditioner constituent, 0-10% wt. of a foam stabilizer constituent; at least 70% wt. of water, and optionally one or more of optional constituents which may be used to impart an aesthetic benefit, e.g., color, fragrance, or a further technical benefit, e.g., viscosity adjustment, to the liquid compositions, characterized in that: (a) the weight ratio of the germicidally effective quaternary ammonium and cationic conditioner constituent to the anionic surfactant constituent is not less than 0.6; and/or, (b) the weight ratio of the germicidally effective quaternary ammonium surfactant compound to the cationic conditioner constituent is less than 0.14; and/or, (c) the ratio of the cationic conditioner constituent to the anionic surfactant constituent is at least 0.5; and, (d) the pH of the liquid composition is between about 3.5 and about 7.5. | 2013-08-15 |
20130210924 | Dosage Regimen of Diaryl Sulfide Derivatives - A compound of formula (I) wherein X is O, S, SO or SO | 2013-08-15 |
20130210925 | SUBUNGUICIDE, AND METHOD FOR TREATING ONYCHOMYCOSIS - Onychomycosis is a fungal infection of the nail bed and is difficult to treat topically because penetration of the nail plate is difficult, and systemic antifungal treatments are prone to side effects and drug interactions. The present invention treats onychomycosis by applying an antifungal composition to the nail bed directly using a solid, semi-solid, or flowable carrier. The carrier can be in the form of a semi-solid into which the user digs and scrapes the nail, a solid carrier can be inserted directly under the nail in contact with the nail bed, or a flowable composition can be injected in contact with the nail bed. | 2013-08-15 |
20130210926 | GLYCYRRHETINIC ACID DERIVATIVES - The present invention relates to novel derivatives of glycyrrhetinic acid, compositions comprising said derivatives and their use in the treatment of conditions or diseases that benefits from an upregulation of PPARγ and/or a downregulation of the expression or activity of one or more specificity (Sp) proteins, such as cancer, diabetes and Huntington's disease. | 2013-08-15 |
20130210927 | Method of Administering an Interomone to an Animal to Modify the Animals Behavior over an Extended Period of Time - A device or collar having a matrix into which an interomone is incorporated in an amount from between about 0.001% and about 5% by weight of the device is described for the modification of undesirable or harmful stress-related behaviors or other behaviors of physiology in a variety of vertebrate species over an extended period of time, as well as methods of using the device to modify behaviors of a variety of vertebrate species over an extended period of time. | 2013-08-15 |
20130210928 | NOVEL BIPHENYL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PREPARING NOVEL BIPHENYL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING DIABETES COMPLICATIONS - The present invention provides a novel biphenyl compound or pharmaceutically acceptable salts thereof, methods for preparing the same, and pharmaceutical compositions for preventing or treating diabetic complications containing the same as an active ingredient. Novel biphenyl compounds, according to the present invention, effectively suppress generation activity of advanced glycation end products, which cause diabetic complications and are a criterion for evaluating the effectiveness of a treating agent for diabetic complications, and show an excellent therapeutic effect on retina blood vessels, increased occludin, and decreased angiogenic growth factor in actual diabetic retinopathy induced retina. Thus, novel biphenyl compounds according to the present invention can be used effectively as an active ingredient in compositions for preventing or treating diabetic complications such as diabetic retinopathy. | 2013-08-15 |
20130210929 | TOPICAL GERMICIDAL COMPOSITIONS - Topical germicidal compositions for application to the epidermis comprise: 50-85% wt, of an alcohol constituent comprising one or more C | 2013-08-15 |
20130210930 | ORGANOPOLYSILOXANE AND USE THEREOF AS SURFACTANT, POWDER TREATMENT AGENT, THICKENING AGENT OF OIL-BASED RAW MATERIAL OR GELLING AGENT. GEL AND EMULSION COMPOSITIONS, AS WELL AS, PREPARATIONS FOR EXTERNAL USE AND COSMETICS COMPRISING THE SAME - The present invention provides a co-modified organopolysiloxane having a specified chemical structure in which a sugar alcohol-modified group and a silylalkyl group having a siloxane dendron structure, and optionally a long-chain hydrocarbon group are present. The co-modified organopolysiloxane is blended, as a surfactant, a powder treatment agent, a gelling agent or the like, or as a cosmetic raw material together with powder (s), oil agent (s) or the like, in a preparation for external use, and in particular, a cosmetic. | 2013-08-15 |
20130210931 | BIS-(ALPHA-AMINO)-DIOL-DIESTER-CONTAINING POLY (ESTER AMIDE) AND POLY (ESTER URETHANE) COMPOSITIONS AND METHODS OF USE - The present invention provides biodegradable, biocompatible bis-(α-amino acyl)-diol-diester-containing poly(ester amide) (PEA) and poly(ester urethane) (PEUR) co-polymer compositions with mechanical properties that can be readily tailored by selection of various combinations and proportions of the building blocks of the co-polymers. The compositions are suitable for use in production of drug-releasing biodegradable particles and implantable surgical devices, such as stents and internal fixation devices. The co-polymer compositions, particles and surgical devices biodegrade in vivo by enzymatic action to release bioactive agents in a controlled manner over time as well as biocompatible breakdown products, including one to multiple different amino acids. | 2013-08-15 |
20130210932 | NOVEL CATIONIC THICKENERS USABLE OVER A WIDE PH RANGE, METHOD FOR THE PREPARATION THEREOF, AND COMPOSITION CONTAINING SAME - Positive latex including an oil phase, an aqueous phase, at least one water-in-oil emulsifying system, and a linear, branched or cross-linked cationic polyelectrolyte resulting from the polymerization, for 100 mol %, of: a) a molar ratio >40% and ≦99% of monomer units originating from at least one cationic monomer; b) a molar ratio ≧1% and <60% of monomer units originating from N-(2-hydroxyethyl)acrylamide; c) optionally, a molar ratio >0% and <30% of monomer units originating from at least one neutral monomer other than the N-(2-hydroxyethyl)acrylamide, on the condition that the molar ratio is strictly less than that of the monomer units originating from N-(2-hydroxyethyl)acrylamide; and d) optionally, a molar ratio >0% and ≦1% of a diethylene or polyethylene cross-linking monomer. A method for preparing and using the positive latex as a thickener for cosmetic or pharmaceutical compositions is also described. | 2013-08-15 |
20130210933 | NOVEL USES OF ESTERAMIDE COMPOUNDS - The use of an esteramide compound, alone or as a mixture of the following formula (I): | 2013-08-15 |
20130210934 | FLAVORING AGENTS CONTAINING BIO-DERIVED 1,3-PROPANEDIOL AND ITS CONJUGATE ESTERS - Biodegradable flavoring agent compositions comprising 1,3-propanediol are provided, and the 1,3-propanediol in the composition is biologically derived. The compositions exhibit a lower anthropogenic CO | 2013-08-15 |
20130210935 | OPERATION OF PROCESSES WHICH EMPLOY A CATALYST THAT DEACTIVATES OVER TIME - A method of operating a process for catalytically converting one or more reactants to one or more products using a fluid bed reactor containing a catalyst which deactivates over time includes, during a catalyst campaign, in a step A, gradually increasing an operating temperature of the reactor to counteract the negative effect of catalyst deactivation on a conversion rate of the one or more reactants. The operating temperature is not allowed to exceed a selected maximum operating temperature. Thereafter, in a step B, catalyst is added which has the tendency to increase the conversion rate of the one or more reactants into the reactor, and the operating temperature of the reactor is reduced to counteract to at least some extent the effect of the added catalyst on the conversion rate of the one or more reactants. The operating temperature remains above a selected minimum operating temperature during step B. Steps A and B are repeated until the end of the catalyst campaign or until the end of a production run. | 2013-08-15 |
20130210936 | Catalysts for Converting Acetic Acid to Acetone - The present invention relates to a process for the formation of acetone from acetic acid. The process is conducted at an elevated temperature of above 225° C. by contacting a feed stream containing acetic acid, and an optional carrier gas, with a catalyst. The catalyst comprises a support that is favorable for the production of acetone. The support may comprise titania, zirconia, ceria, silica, iron oxide, and carbon, but preferably is titania, zirconia, and ceria. | 2013-08-15 |
20130210937 | Industrial Procedure for the Obtaining of Lower Alcohols From Solar Energy - The procedure according to the invention allows the obtaining of lower alcohols from the solar energy produced at a high temperature solar thermal power plant which provides, from an energy point of view, the power supply necessary for every step of the procedure, supplying both the electricity power necessary to perform the intermediate steps of the procedure and, essentially, the products involved in the different steps (H | 2013-08-15 |
20130210938 | PROCESS FOR THE PRODUCTION OF SUBSTITUTE NATURAL GAS - In a process for the production of substitute natural gas, a feed gas is provided to a first and/or second and/or subsequent bulk methanator. The feed gas is subjected to methanation in the presence of a suitable catalyst. An at least partially reacted stream from the first bulk methanator is removed and supplied to the second and/or subsequent bulk methanator where it is subjected to further methanation. A product stream from the final bulk methanator is passed to a trim methanator train where it is subjected to further methanation. A recycle stream is removed downstream of the first, second or subsequent bulk methanator, and, in any order, passed through a compressor, subjected to cooling and then supplied to a trim and/or recycle methanator for further methanation before being recycled to the first and/or second and/or subsequent methanator. | 2013-08-15 |
20130210939 | FISCHER-TROPSCH CATALYST REGENERATION - A process for the regeneration of deactivated catalyst from a Fischer-Tropsch synthesis reactor, the catalyst being a supported cobalt catalyst. The process comprises the following steps: a withdrawal step, in which a portion of deactivated catalyst together with liquid hydrocarbon is withdrawn from the reactor; a concentration step, in which the concentration of the catalyst in the liquid hydrocarbon is increased; a calcination step, in which the deactivated catalyst composition is subjected to an oxidising gas to oxidise carbonaceous material contained in the deactivated catalyst in to gaseous oxides of the components of the carbonaceous material; and a reactivation step, in which the deactivated catalyst composition is reactivated to produced a regenerated catalyst. | 2013-08-15 |
20130210940 | CATALYTICALLY ACTIVE BODY FOR THE SYNTHESIS OF DIMETHYL ETHER FROM SYNTHESIS GAS - The invention relates to a catalytically active body for the synthesis of dimethyl ether from synthesis gas. In particular, the invention relates to an improved catalytically active body for the synthesis of dimethyl ether, whereby the components of the active body comprise a defined particle size distribution. Furthermore, the present invention concerns a method for the preparation of a catalytically active body, the use of the catalytically active body and a method for preparation of dimethyl ether from synthesis gas. | 2013-08-15 |
20130210941 | PROCESS FOR PREPARING OLEFINS FROM SYNTHESIS GAS USING A COBALT AND MANGANESE CONTAINING CATALYST - The invention relates to a process for preparing olefins from synthesis gas, wherein the synthesis gas is contacted with a catalyst which contains cobalt, manganese and a third element selected from the group consisting of aluminium, gallium, indium, thallium, tin, lead and bismuth. Further, the invention relates to a process for preparing such catalyst, and to the catalyst so obtained. | 2013-08-15 |
20130210942 | MODIFIED FISCHER-TROPSCH MONOLITH CATALYSTS AND METHODS FOR PREPARATION AND USE THEREOF - Disclosed are hybrid synthesis gas conversion catalysts containing at least one Fischer-Tropsch component and at least one acidic component deposited on a monolith catalyst support for use in synthesis gas conversion processes and methods for preparing the catalysts. Also disclosed are synthesis gas conversion processes in which the hybrid synthesis gas conversion catalysts are contacted with synthesis gas to produce a hydrocarbon product containing at least 50 wt % C | 2013-08-15 |
20130210943 | Dispersion Composition of Fluorine-Containing Ion Exchange Resin - The disclosure includes dispersion compositions of fluorine-containing ion exchange resin. | 2013-08-15 |
20130210944 | Expandable Functional TFE Copolymer Fine Powder, the Expandable Functional Produdcts Obtained Therefrom and Reaction of the Expanded Products - A functional TFE copolymer fine powder is described, wherein the TFE copolymer is a polymer of TFE and at least one functional comonomer, and wherein the TFE copolymer has functional groups that are pendant to the polymer chain. The functional TFE copolymer fine powder resin is paste extrudable and expandable. Methods for making the functional TFE copolymer are also described. The expanded functional TFE copolymer material may be post-reacted after expansion. | 2013-08-15 |
20130210945 | CROSS-LINKED ELASTOMER COMPOSITION AND PRODUCT INCLUDING SUCH A COMPOSITION - The invention relates to a cross-linked elastomer composition including: an ethylene/alpha-olefin multiblock copolymer comprising polymerized ethylene and alpha-olefin units, an elastomer including a block copolymer having at least two, identical or different, aromatic blocks which are separated by at least one elastomer block, and a cross-linkable polymer, for example, a diene elastomer. The invention also relates to a product including the composition, and to the use of such a product as a seal. | 2013-08-15 |
20130210946 | BLOWING AGENTS, FOAM PREMIXES AND FOAMS CONTAINING HALOGENATED OLEFIN BLOWING AGENT AND ADSORBENT - The invention provides polyurethane and polyisocyanurate foams and methods for the preparation thereof. More particularly, the invention relates to closed-celled, polyurethane and polyisocyanurate foams and methods for their preparation. Preferably, the foams are produced with a polyol premix composition which comprises a combination of a hydrohaloolefin blowing agent, a polyol, a catalyst and an adsorbent material. | 2013-08-15 |
20130210947 | Water-Absorbing Polymer Particles with High Free Swell Rate and High Permeability - A process for producing water-absorbing polymer particles with high free swell rate and high permeability by polymerization of an aqueous monomer solution or suspension to give an aqueous polymer gel, wherein a thermal blowing agent essentially free of inorganic acid anions is mixed into the polymer gel, and subsequent thermal drying of the polymer gel. | 2013-08-15 |
20130210948 | Polystyrene Blends - A method of preparing a polystyrene blend that includes combining a first polystyrene composition having a first melt flow index with a second polystyrene composition having a second melt flow index and forming a polystyrene blend, the second melt flow index being at least 2 dg/min higher that the first melt flow index. The polystyrene blend has an observed tensile strength value greater than 3% above the expected tensile strength value. The second polystyrene composition can include a recycled polystyrene material, which can include expanded polystyrene. An alternate method of preparing the polystyrene blend includes combining a polystyrene composition with a styrene monomer to form a reaction mixture, polymerizing the reaction mixture and obtaining a polystyrene blend, where the polystyrene containing composition has a melt flow index at least 2 dg/min higher than the melt flow index of the styrene monomer after it has been polymerized. | 2013-08-15 |
20130210949 | Renewable Polyester Compositions having a Low Density - A thermoplastic composition that contains a rigid renewable polyester and has a voided structure and low density is provided. To achieve such a structure, the renewable polyester is blended with a polymeric toughening additive to form a precursor material in which the toughening additive can be dispersed as discrete physical domains within a continuous matrix of the renewable polyester. The precursor material is thereafter stretched or drawn at a temperature below the glass transition temperature of the polyester (i.e., “cold drawn”). This creates a network of voids located adjacent to the discrete domains, which as a result of their proximal location, can form a bridge between the boundaries of the voids and act as internal structural “hinges” that help stabilize the network and increase its ability to dissipate energy. The present inventors have also discovered that the voids can be distributed in a substantially homogeneous fashion throughout the composition. | 2013-08-15 |
20130210950 | REACTION SYSTEM FOR PREPARING POLYURETHANE MICROCELLULAR FOAM, A POLYURETHANE MICROCELLULAR FOAM AND THE USE THEREOF - The present invention relates to a reaction system for preparing polyurethane microcellular foam, a polyurethane microcellular foam and the use thereof. The reaction system for preparing polyurethane microcellular foam comprises isocyanate prepolymer, polyols, catalysts and chain extenders. The isocyanate prepolymer is a reaction product of polyisocyanates and polyester polyols, wherein the polyester polyols comprise 10-60 wt. % succinic acid units, based on 100 wt. % of the polyester polyols, the NCO content of the isocyanate prepolymer is 13-30 wt. %, based on 100 wt. % of isocyanate prepolymer. By using the reaction components provided in the present invention, the demould time for preparing the polyurethane microcellular foam can be reduced. The obtained polyurethane microcellular foam, which possesses good physical and mechanical properties, is particularly suitable to prepare shoes. | 2013-08-15 |
20130210951 | POLYOLS SUITABLE FOR HOT MOLDED FOAM PRODUCTION WITH HIGH RENEWABLE RESOURCE CONTENT - Polyols are produced by an alkoxylation process in which a vegetable oil containing hydroxyl functional groups is combined with a DMC catalyst to form a mixture, the DMC catalyst is then activated by adding ethylene oxide and/or propylene oxide to the vegetable oil/catalyst mixture, and ethylene oxide and propylene oxide are added to the mixture containing activated DMC catalyst in amounts such that the total of percentage of ethylene oxide in the polyol plus percentage of primary hydroxyl groups in the polyol produced is from 50 to 77% and the percentage of primary hydroxyl groups is at least 30% but less than 50%. These polyols are useful for the production of molded polyurethane foams, particularly, hot-cure molded polyurethane foams. | 2013-08-15 |
20130210952 | SEALING SHELL AND USE THEREOF, DEVICE AND METHOD FOR PRODUCING FOAM-MOLDED PARTS - The invention proposes a sealing shell ( | 2013-08-15 |
20130210953 | BIOMATERIAL COMPOSITIONS - Biomaterial compositions comprising organosilicon monomers (such as silorane monomers) and chemical curing systems or dual chemical/light curing systems, in conjunction with optional tetraoxaspiro[5.5]undecanes (“TOSUs”) and/or fillers. The present invention is directed to biomaterial compositions, as well as methods for manufacturing the same, and methods of using the compositions. The biomaterial composition comprises one or more organosilicon monomers (such as a silorane) and a chemical curing system or dual chemicaVlight curing system for polymerizing the 10 monomer(s). The compositions may include one or more tetraoxaspiro[5.5]undecanes “TOSUs”) and/or fillers. Accelerators (such as photoacids), photosensitizers, and/or electron donors may also be included in the composition as appropriate. | 2013-08-15 |
20130210954 | POLYMERISABLE PHOTOINITIATORS FOR LED CURABLE COMPOSITIONS - A polymerisable photoinitiator according to Formula (I): | 2013-08-15 |
20130210955 | RESIN COMPOSITE MATERIAL AND METHOD FOR PRODUCING RESIN COMPOSITE MATERIAL - Provided is a resin composite material in which a carbon material with a graphene structure is dispersed in a synthetic resin and which has a high mechanical strength and a low linear expansion coefficient and a method for producing the resin composite material. A resin composite material contains a synthetic resin and a carbon material with a graphene structure dispersed in the synthetic resin, wherein the synthetic resin is grafted onto the carbon material and the grafting ratio thereof onto the carbon material is 5% to 3300% by weight. A method for producing a resin composite material includes the steps of: preparing a resin composite containing a synthetic resin and a carbon material with a graphene structure dispersed in the synthetic resin; and grafting the synthetic resin onto the carbon material concurrently with or after the step of preparing the resin composite. | 2013-08-15 |
20130210956 | Cured Triacylglycerol Oligomers and Methods of Making and Using Same - A process is disclosed for curing a composition containing a triacylglycerol oligomer which includes exposing the composition to ultraviolet radiation to form a cured product. The composition can also include any or all of the following: a pigment, an initiator, a fatty acid methyl ester, a surfactant, a drying agent, and other additives. | 2013-08-15 |
20130210957 | ACTIVE ENERGY RAY-CURABLE RESIN COMPOSITION, NANO RIDGE/GROOVE STRUCTURE USING SAME AND PRODUCTION METHOD FOR SAID STRUCTURE, AND WATER REPELLENT ARTICLE PROVIDED WITH NANO RIDGE/GROOVE STRUCTURE - Disclosed is an activation energy ray-curable resin composition comprising 70 to 95 parts by mass of a multifunctional monomer (A) which has a surface free energy of 37 mJ/m | 2013-08-15 |
20130210958 | SILICONE IMPRESSION MATERIAL HAVING HIGH HYDROPHILICITY - Provided is a silicone impression material with high hydrophilicity that exhibits instantaneous hydrophilicity before being cured, that exhibits high hydrophilicity after being cured, that has preferable properties for a dental impression material, and that has good preservation stability. A sorbitan fatty acid ester based surfactant and a nonionic surfactant composed of polyester modified silicone are used in combination as a hydrophilizing agent not containing a siloxane polymer and a hydrophilizing agent containing a siloxane polymer, respectively. | 2013-08-15 |
20130210959 | DENTAL COMPOSITIONS COMPRISING SEMI-CRYSTALLINE RESIN AND NANOCLUSTER FILLER - Curable dental compositions, dental articles, and methods of making or using such compositions or articles are described. In one embodiment, the curable dental restoration composition comprises a resin system comprising a free-radically polymerizable semi-crystalline resin having a molecular weight no greater than 2000 g/mole and at least 50 wt-% of nanocluster filler. | 2013-08-15 |
20130210960 | CALCIUM PARTICLE-EMBEDDED, SNAP-TO-DOUGH, HIGH-VISCOSITY BONE CEMENT - The present invention relates to a composition comprising: a) a first component comprising a poly(methyl met 5 hacrylate) (PMMA), a contrast agent, a radical donor and calcium based particles; and b) a second component comprising methyl methacrylate (MMA), a radical scavenger, and a polymerization accelerator; wherein the composition has an average setting time of about 13 minutes. | 2013-08-15 |
20130210961 | Epoxy Composition with Crystallization Inhibition - An epoxy resin composition formed, at least in part, as the reaction product of a mixture comprising 95 and 99 wt % of an epoxy component comprising one or more diglycidyl ethers of Bisphenol A and between 1 and 5 wt % of an additive component comprising one or more aromatic amines, wherein each aromatic amine contains no more than two amine hydrogen atoms is provided. Also provided is a method of using the epoxy resin composition including incorporating the epoxy resin composition into a coating, an adhesive, a sealant, a casting, a laminate, or a composite. | 2013-08-15 |
20130210962 | GLASS COMPOSITION FOR PRODUCING HIGH STRENGTH AND HIGH MODULUS FIBERS - A glass composition including SiO | 2013-08-15 |
20130210963 | REDISPERSIBLE DRY COMPOSITION OF POLYMER FINISHES OR OTHER PRODUCTS FOR THE CONSTRUCTION - The invention relates to improved non-efflorescing cement-free and water-dispersible powder building material compositions comprising a homopolymer or copolymer as binder, useful for the preparation of wet formulations of plasters grouts, waterproofing coatings or mortars for the construction and the civil engineering industry. Redispersible dry composition of polymer finish comprising: a powdery organic binder included a polymer obtained by spray-drying or lyophilisation of a dispersion containing said polymer and a protective colloid; a deprotection agent; a specific adsorbent filler; and/or a load; and/or a water retentive agent; and/or a mineral rheological agent; and/or a defoamer; and/or a biocide; and/or a pigment. The invention also refers to the methods of preparation of these dry compositions and wet formulations, the application of these latter onto the surface of buildings or civil engineering works, the so obtained coatings as well as the so coated elements. The applications of these wet formulations can be also hardened joints or other hardened products for the construction as well as hardened mass objects. All these hardened products are remarkably water-resistant, non efflorescent and easy to obtain. | 2013-08-15 |
20130210964 | Composite Polymer - A composition comprising 10 to 50 weight % wood pulp fiber, 45 to 85 weight % thermoplastic polymer and 0.1 to 5 weight % clear mineral oil having a specific gravity less than water. A composition comprising 65 to 85 wt % wood pulp fiber, 15 to 35 wt % thermoplastic polymer and 0.1 to 5 weight % mineral oil having a specific gravity less than water. The wood pulp fiber can be bleached chemical wood pulp fiber. | 2013-08-15 |
20130210965 | Composite Polymer - A composition comprising 10 to 50 wt % wood pulp fiber and 45 to 85 wt % thermoplastic polymer wherein the dilution level for detection in a bag at 40° C. is equal to or less than 450 as determined by ASTM E679. | 2013-08-15 |
20130210966 | BITUMINOUS COMPOSITION - The invention provides a bituminous composition comprising a bitumen in an amount ranging from 20 to 80% wt, a copolymer comprising one or more vinyl aromatic compounds and one or more conjugated dienes, in an amount of 0.1 to 7 % wt, and sulphur in an amount of 20 to 60% wt, all percentages based on the weight of bitumen, copolymer and sulphur. It further provides a process for making this composition and asphalt compositions comprising such bituminous composition. | 2013-08-15 |
20130210967 | AQUEOUS BINDER COMPOSITION - Aqueous binder composition for granular and/or fibrous substrates | 2013-08-15 |
20130210968 | Flame-Retardant Polyester Compounds - The invention relates to flame-retardant polyester compounds comprising as component A 40% to 89.9% by weight of thermoplastic polyesters, as component B 5% to 25% by weight of phosphinic salt of the formula (V) and/or diphosphinic salt of the formula (VI) and/or polymers thereof, in which R | 2013-08-15 |
20130210969 | FEEDBACK ACTIVE COATINGS WITH SENSITIVE CONTAINERS BASED ON NANO-, MICRO-, MINI-, AND MACROEMULSIONS OF DIRECT OR REVERSED TYPE - Nano- or microsized containers include either a water immiscible or sparingly miscible core dispersible in aqueous dispersion medium or a water miscible core dispersible in non-aqueous dispersion medium and a core-soluble active agent selected from the group consisting of corrosion inhibitors, catalysts, accelerators of catalysts, adhesives, sealants, polymerizable compounds (monomers), surfactants, lubricants, antifouling agents, water repelling materials and their mixtures, and a stimulus-sensitive polymer/polyelectrolyte shell that encapsulates the core-soluble active agent and releases the encapsulated agent in response to an external stimulus selected from the group consisting of humidity, ionic strength, pH, temperature, mechanical stress, constant and alternating magnetic or electromagnetic fields, corrosion products, electric current, and electrochemical potential. | 2013-08-15 |
20130210970 | MELAM GRANULATE MATERIAL AND PROCESS FOR PREPARATION THEREOF - The invention relates to a method for producing a free flowing flame retardant material, comprising steps of i. preparing an aqueous slurry from a freshly prepared moist melam having a water content of at least 8 wt. %, relative to the total weight of the moist melam, the slurry comprising water, melam and a water soluble polymeric binding agent, wherein the melam is present in an amount of 5-35 wt. % relative to the total weight of the slurry, and the water soluble polymeric binding agent is present in an amount of 0.5-8 wt. % relative to the total amount of melam and the water soluble polymeric binding agent; ii. drying the slurry in a fluid bed to form a granulate material; and iii. collecting the resulting granulate material. The invention also relates to a melam granulate material, obtainable by said process. | 2013-08-15 |
20130210971 | SPUN-DYED ARAMID FIBERS - Spun-dyed aramid fibers, wherein spun-dyeing was performed with a completely organic pigment exhibiting the chemical structure of formula (I): | 2013-08-15 |
20130210972 | MOLECULES CARRYING ASSOCIATIVE GROUPS AND USE THEREOF AS PLASTICISERS - The invention relates to the field of plasticisers, compounds used as additives in polymers for facilitating the transformation thereof or modifying the mechanical properties thereof, especially rigidity. | 2013-08-15 |
20130210973 | PROCESS FOR IMPROVING THE FLOW PROPERTIES OF POLYMER MELTS - A process for improving the flow properties of a melt containing a thermoplastic polymer, which comprises incorporating 0.005% to 0.5% by weight, relative to the weight of the thermoplastic polymer, of one or more additives selected from the group consisting of organic and inorganic compounds with needle-like morphology in their solid state into said thermoplastic polymer prior to or during melt processing. | 2013-08-15 |
20130210974 | Plasticized Polyvinyl Chloride Composition with Flame Retardant - A highly flame retardant plasticized polyvinyl chloride composition includes a mixture of a dialkyl or dialkenyl tetrahalophthalate and a brominated/chlorinated paraffin. The composition exhibits an absence of brittleness, and substantial flexibility at low temperatures. The composition can be used to form sheet materials, molding compositions, roofing materials, PVC formed jackets and insulation for wire and cable products. | 2013-08-15 |